Previous close | 125.85 |
Open | 127.24 |
Bid | 125.03 x 800 |
Ask | 125.59 x 800 |
Day's range | 125.05 - 128.70 |
52-week range | 99.14 - 134.63 |
Volume | |
Avg. volume | 8,233,711 |
Market cap | 317.26B |
Beta (5Y monthly) | 0.39 |
PE ratio (TTM) | 139.18 |
EPS (TTM) | 0.90 |
Earnings date | 30 Jul 2024 |
Forward dividend & yield | 3.08 (2.46%) |
Ex-dividend date | 16 Sept 2024 |
1y target est | 143.28 |
RAHWAY, N.J., July 26, 2024--Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Advanced Bladder Cancer
On Tuesday, Merck & Co Inc (NYSE:MRK) shared topline results from its Phase 2b/3 clinical trial (MK-1654-004) of clesrovimab (MK-1654). Clesrovimab is the company’s investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease. Clesrovimab met its primary safety and efficacy endpoints in the trial, including reducing medically attended lower respiratory infections (MALRI) caused by RSV through Day 150. Participants were randomized to
RAHWAY, N.J., July 23, 2024--Merck Announces Fourth-Quarter 2024 Dividend